Michel Sadelain Awarded 2019 Inserm International Prize

Share
Print
Michel Sadelain

CAR T pioneer Michel Sadelain

 

Michel Sadelain, Director of the Center for Cell Engineering and the incumbent of the Stephen and Barbara Friedman Chair at Memorial Sloan Kettering, received the 2019 International Prize from Inserm (Institut national de la santé et de la recherche médicale), or the French National Institute of Health and Medical Research. He accepted the award at a 20th anniversary Inserm ceremony at the Collège de France in Paris on December 10.

Inserm is a government research agency akin to the National Institutes of Health that is dedicated entirely to promoting health, advancing knowledge about life and disease, and increasing public health research.

Dr. Sadelain received the award for his research on chimeric antigen receptors (CARs) and their use in providing tailored cancer treatment to patients. This immunotherapy strategy based on T cell engineering was developed with Isabelle Rivière, Director of the Cell Therapy and Cell Engineering Facility at MSK.

Dr. Sadelain has also received the 2018 Pasteur-Weizmann/Servier International Prize and the 2019 Jacob and Louise Gabbay Award in Biotechnology and Medicine.

Congratulations to Dr. Sadelain on this significant award.

What is CAR T?
Explore how MSK scientists and clinicians are using an immunotherapy called chimeric antigen receptor (CAR) T cell therapy to beat cancer.
Learn more